Results for DNA

Dr. Zhou’s outstanding research interests include mitosis-coupled DNA methylation drift and inference of cell-type-specific epigenetic signals. He developed multiple computational tools for analyzing DNA methylation data and has actively contributed to cancer genomics data analysis.

Dr. Tong investigates cytokine receptor signaling in normal and neoplastic hematopoietic development. She uses integrated approaches encompassing biochemistry, molecular biology, mouse models, and primary human samples to understand signaling events emanating from cytokine receptors that regulate the development of hematopoietic stem/progenitor cells.

Dr. Nader is an assistant professor in the Department of Pathology and Laboratory Medicine at CHOP. His research topics are focused on the nuclear mechano-sensing of cells that grow and move within dense microenvironments such as tumor microenvironment, interstitial space, or densely packed tissue.

Dr. Diskin's research is focused on translational genomics in childhood cancers. Her laboratory seeks to identify the genetic basis of childhood cancers by combining quantitative computational methods with rigorous "wet-lab" experimental approaches. In parallel, she has developed, and is applying, a proteogenomic approach to identify novel immunotherapeutic targets for high-risk and relapsed pediatric malignancies.

Dr. Weitzman's research program aims to understand host responses to virus infection, and the cellular environment encountered and manipulated by viruses. He studies multiple viruses in an integrated experimental approach that combines biochemistry, molecular biology, genetics, and cell biology.

Dr. Wallace is a geneticist and evolutionary biologist who founded the field of mitochondrial medicine 40 years ago. He investigates the role of mitochondria in human evolution, health, and disease.

The overarching goal of my research is to help prevent chronic diseases in later life, by focusing on energetic behaviors (sleep, diet, and physical activity) and their impact on body composition during growth and development.

The cure rate for children with neuroblastoma is unacceptable, making it imperative that new therapies are developed. Dr. Bosse's laboratory is focused on discovering and developing new neuroblastoma cell surface immunotherapeutic targets. Along with his colleagues, Dr. Bosse's aim is to capitalize on the robust differential expression of these molecules with immune-based therapies and also define their mechanisms of overexpression and roles in tumorigenesis.

Dr. Bassing's research program focuses on the genetic, epigenetic, and biochemical mechanisms by which mammals develop their immune systems while suppressing autoimmunity and genomic aberrations that cause leukemia or lymphoma.

Dr. Felix uses molecular, biochemical, cellular and in vivo methods to investigate the pathobiology of leukemias with KMT2A (MLL) translocations. Leukemias with these translocations affect infants and young children or occur as a complication of type II topoisomerase (TOP2) poison chemotherapies used for anti-cancer treatment. She aims to develop better treatment and prevention approaches for these leukemias, which have a poor prognosis.